ArticleFrontiers in oncology2022

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.

Wongeun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.